EARLSDON PHARMA LTD

Company Registration Number:
14586363 (England and Wales)

Unaudited abridged accounts for the year ended 31 January 2025

Period of accounts

Start date: 01 February 2024

End date: 31 January 2025

EARLSDON PHARMA LTD

Contents of the Financial Statements

for the Period Ended 31 January 2025

Balance sheet
Notes

EARLSDON PHARMA LTD

Balance sheet

As at 31 January 2025


Notes

2025

13 months to 31 January 2024


£

£
Fixed assets
Intangible assets: 3 640,618 688,480
Tangible assets: 4 47,440 41,078
Total fixed assets: 688,058 729,558
Current assets
Stocks: 109,250 25,000
Debtors: 5 147,170 136,324
Cash at bank and in hand: 275,721 180,123
Total current assets: 532,141 341,447
Creditors: amounts falling due within one year:   (316,612) (268,596)
Net current assets (liabilities): 215,529 72,851
Total assets less current liabilities: 903,587 802,409
Total net assets (liabilities): 903,587 802,409
Capital and reserves
Called up share capital: 100,000 100,000
Share premium account: 689,768 689,768
Profit and loss account: 113,819 12,641
Shareholders funds: 903,587 802,409

The notes form part of these financial statements

EARLSDON PHARMA LTD

Balance sheet statements

For the year ending 31 January 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 13 August 2025
and signed on behalf of the board by:

Name: IMRAZ GUL ASHRAF
Status: Director

The notes form part of these financial statements

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2025

2. Employees

2025 13 months to 31 January 2024
Average number of employees during the period 7 8

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2025

3. Intangible Assets

Total
Cost £
At 01 February 2024 736,342
At 31 January 2025 736,342
Amortisation
At 01 February 2024 47,862
Charge for year 47,862
At 31 January 2025 95,724
Net book value
At 31 January 2025 640,618
At 31 January 2024 688,480

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2025

4. Tangible Assets

Total
Cost £
At 01 February 2024 51,346
Additions 20,788
At 31 January 2025 72,134
Depreciation
At 01 February 2024 10,268
Charge for year 14,426
At 31 January 2025 24,694
Net book value
At 31 January 2025 47,440
At 31 January 2024 41,078

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2025

5. Debtors

2025 13 months to 31 January 2024
££
Debtors due after more than one year: 147,170 136,324